(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) Wednesday announced positive top-line results from the Phase 2b ATI-1777-AD-202 study of ATI-1777 in patients with mild to severe atopic dermatitis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback